The attempt to address the most menacing threat faced by mankind finds a hope. At Bugworks, our world class team aims to create a much needed respite to AMR through our broad spectrum anti-bacterial assets.
Saving mankind from the threat of AMR using our path-breaking discoveries
Know More
Bugworks secures support from US Government's Defense Threat Reduction Agency (DTRA) to validate its clinical asset against the toughest bacterial biothreats
Dr. Oppel Greeff, Bugworks’ investor and member of SAB, wins the prestigious Havengaprize by the South Africa Academy of Art and Science
Bugworks’ CEO interviewed by the Financial Express as part of a story done on World innovation day!
Anand Anandkumar, Bugworks’ CEO has been re-nominated into the Board of AMR Industry Alliance and will serve as key member of the Biotech Working Group within this global alliance.
